COST-EFFECTIVENESS OF NILOTINIB VERSUS IMATINIB AS FIRST-LINE TREATMENT FOR NEWLY DIAGNOSED PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE (CML-CP) IN RUSSIAN FEDERATION

被引：0
|
作者：
Yagudina, R. [1 ]
Kulikov, A. [1 ]
Komarov, I [1 ]
机构：
[1] IM Sechenov First Moscow State Med Univ, Moscow, Russia
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.2132
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A426 / A426
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of nilotinib versus imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-positive (Ph plus ) chronic myeloid leukemia in the chronic phase (CML-CP): Swedish perspective
    Ovanfors, A.
    Stephens, J.
    Snedecor, S. J.
    Patel, D.
    Ji, X.
    Carpiuc, K. T.
    Coombs, J.
    Botteman, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] COST EFFECTIVENESS OF NILOTINIB VERSUS IMATINIB AS FIRST LINE TREATMENT FOR NEWLY DIAGNOSED HONG KONG (HK) PATIENTS WITH CHRONIC PHASE, PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE (CML-CP) IN HONG KONG
    Tse, V
    Liu, H.
    Botteman, M.
    Mcghee, S.
    Lee, V. W.
    Lee, K. K.
    VALUE IN HEALTH, 2012, 15 (04) : A217 - A218
  • [3] COST-EFFECTIVENESS OF SECOND-LINE NILOTINIB VERSUS DASATINIB FOR THE TREATMENT OF PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA-CHRONIC PHASE (PH plus CML-CP) IN ITALY
    Maheshwari, V
    Tran, D.
    Agostoni, G.
    Filioussi, K.
    Viana, R.
    VALUE IN HEALTH, 2019, 22 : S470 - S470
  • [4] COST-EFFECTIVENESS OF NILOTINIB VERSUS DASATINIB FOR THE SECOND LINE TREATMENT OF PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP), RESISTANT OR INTOLERANT TO IMATINIB, IN FRAME OF RUSSIAN HEALTHCARE SYSTEM
    Goyert, N.
    Tran, D.
    Efremova, E.
    Apostopoulos, C.
    Grima, D.
    VALUE IN HEALTH, 2017, 20 (09) : A441 - A441
  • [5] Long-term estimate of quality-adjusted life expectancy for nilotinib and imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-positive (Ph plus ) chronic myeloid leukemia in the chronic phase (CML-CP)
    Botteman, M.
    Stephens, J.
    Snedecor, S. J.
    Ji, X.
    Hussein, M.
    Coombs, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Nilotinib In the First-Line Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia in Chronic Phase
    Garnock-Jones, Karly P.
    DRUGS, 2011, 71 (12) : 1579 - 1590
  • [7] Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy
    Bonifacio, Massimiliano
    Maheshwari, Vikalp
    Tran, Diana
    Agostoni, Gianluca
    Filioussi, Kalitsa
    Viana, Ricardo
    PHARMACOECONOMICS-OPEN, 2022, 6 (01) : 95 - 104
  • [8] Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy
    Massimiliano Bonifacio
    Vikalp Maheshwari
    Diana Tran
    Gianluca Agostoni
    Kalitsa Filioussi
    Ricardo Viana
    PharmacoEconomics - Open, 2022, 6 : 95 - 104
  • [9] Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    Issaragrisil, Surapol
    Clark, Richard E.
    Reiffers, Josy
    Nicolini, Franck E.
    Pasquini, Ricardo
    Kalaycio, Matt
    Hughes, Timothy P.
    Hochhaus, Andreas
    Kemp, Charisse
    Fan, Xiaolin
    Waltzman, Roger J.
    Saglio, Giuseppe
    Larson, Richard A.
    BLOOD, 2012, 120 (21)
  • [10] Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up
    Saglio, Giuseppe
    LeCoutre, Philipp D.
    Pasquini, Ricardo
    Jootar, Saengsuree
    Nakamae, Hirohisa
    Flinn, Ian W.
    Hochhaus, Andreas
    Hughes, Timothy P.
    Larson, Richard A.
    Hoenekopp, Albert
    Gallagher, Neil J.
    Yu, Richard
    Blakesley, Rick E.
    Kim, Dong-Wook
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 208 - 209
12345